TP53 and gastric cancer: The aforementioned experimental findings demonstrate that baicalin is a useful intervention medication and that the p53-mediated SLC7A11/GPX4/ROS pathway is an excellent therapeutic target for reversing oxaliplatin-resistant gastric cancer.